OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 MillionNewsfile Corp · 6 days ago
Rubenstein Public Relations Named Agency of Record for OS TherapiesGlobeNewsWire · Oct 8, 2026
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine OsteosarcomaNewsfile Corp · Oct 7, 2026
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer TreatmentBenzinga · Oct 6, 2026
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma TrialNewsfile Corp · Oct 6, 2026
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial OfficerNewsfile Corp · Oct 1, 2026OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.18 | -$0.20 | Miss |
| May 18, 2026 | -$0.17 | -$0.27 | Miss |
| Mar 31, 2026 | -$0.14 | -$0.35 | Miss |
| Nov 14, 2025 | -$0.16 | -$0.21 | Miss |
| Aug 19, 2025 | -$0.15 | -$0.19 | Miss |
| May 15, 2025 | -$0.11 | -$0.18 | Miss |